Covigilant Research, LLC Clinical Trials Site Management Organization

Covigilant Research, LLC

Committed To Working Together

Study highlights prognostic factors for Lutetium 177 in mCRPC – Urology Times,

The overall median OS observed with 177Lu was 20.7 months in 125 patients with mCRPC who received treatment on sequential prospective clinical …, The overall median OS observed with 177Lu was 20.7 months in 125 patients with mCRPC who received treatment on sequential prospective clinical …, Read More

Scroll to Top